New shot could tame high blood pressure – early trial underway
NCT ID NCT07297797
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an injectable drug called HRS-9563 in 234 adults with mild to moderate hypertension. Participants are randomly assigned to receive either the drug or a placebo injection. The main goal is to see if HRS-9563 can safely lower average blood pressure over 24 hours after 6 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HRS-9563 injection
- What this could lead to
- If it works, this could provide a new injectable option to help control blood pressure in people with mild to moderate hypertension.
- What could go wrong
- This is an early Phase 2 trial with only 234 participants, so results may not apply to everyone. The drug may not lower blood pressure better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
238 people
The number who actually took part.
- Started
-
Jan 2026
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The subject voluntarily signs the informed consent form. 2. Male or female, aged ≥ 18 years and ≤ 75 years; 3. Patients with mild to moderate hypertension; 4. At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \< 160 mmHg. Exclusion Criteria: 1. Secondary hypertension; 2. Orthostatic hypotension; 3. Type 1 diabetes or poorly controlled type 2 diabetes; 4. Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening; 5. Presence of uncontrolled severe arrhythmia within 6 months prior to screening; 6. Suspected allergy to the investigational drug or any of its components; 7. Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension; 8. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria; 9. Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mild to moderate hypertension are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.